Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Snapshot: After Benlysta Breakthrough, How High The Sky In Lupus?

Executive Summary

Human Genome Sciences' Phase III breakthrough with the biologic Benlysta in lupus has renewed hope in new drugs for a difficult-to-treat disease. The question now, though, is how big can the market grow for this elusive condition, given the high unmet need

You may also be interested in...



Another Blow For Lupus As Lilly’s Tabalumab Fails In Phase III

After Lilly’s monoclonal antibody fails to prove efficacy in two Phase III trials, Lupus Foundation of America pleads with FDA to “allow innovative trial design” for the disease.

Another Blow For Lupus As Lilly’s Tabalumab Fails In Phase III

After Lilly’s monoclonal antibody fails to prove efficacy in two Phase III trials, Lupus Foundation of America pleads with FDA to “allow innovative trial design” for the disease.

Benlysta May Lead Wave Of New Approvals For Lupus Drugs

The looming approval of Benlysta may create an easier pathway to approval for other lupus candidates, while leaving a potentially broad opportunity for other drugs to fill gaps in its label. Start-Up profiles three emerging lupus drug developers: Azano Pharmaceuticals, Resolve Therapeutics and SuppreMol

Related Content

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel